接受替诺福韦艾拉酚胺和恩曲他滨为基础抗逆转录病毒治疗的HIV感染者干血斑中替诺福韦双磷酸盐和恩曲他滨三磷酸盐的服药依从性基准(QUANTI-TAF)
QUANTI-TAF研究纳入84名接受替诺福韦艾拉酚胺/恩曲他滨(TAF/FTC)为基础抗逆转录病毒治疗的HIV感染者,通过可吞服传感器直接测量16周累积和10天依从性,并在干血斑(DBS)中定量替诺福韦双磷酸盐(TFV-DP)和恩曲他滨三磷酸盐(FTC-TP)。结论认为TFV-DP ≥1800 fmol/punches和FTC-TP ≥2.5 pmol/punches代表未增强TAF/FTC方案依从性≥85%的DBS基准,且高依从性人群中低水平病毒血症常见。
要点
- TFV-DP ≥1800 fmol/punches和FTC-TP ≥2.5 pmol/punches为未增强TAF/FTC依从性≥85%的DBS基准。
- 累积依从性≥95%者TFV-DP中位数3344 fmol/punches,85%-<95%者为3117,<85%者为2696。
- 10天依从性≥95%者FTC-TP中位数4.96 pmol/punches,85%-<95%者为4.58,<85%者为3.52。
核心结论
- TFV-DP ≥1800 fmol/punches和FTC-TP ≥2.5 pmol/punches代表未增强TAF/FTC为基础抗逆转录病毒治疗依从性≥85%的干血斑基准。
- 在高依从性的HIV感染者中,低水平病毒血症常见。
研究设计与样本
- QUANTI-TAF研究,纳入84名接受TAF/FTC为基础抗逆转录病毒治疗的HIV感染者,其中女性11%、跨性别者4%,73%主要接受比克替拉韦/TAF/FTC。
- 参与者接受TAF/FTC为基础抗逆转录病毒治疗并共封装可吞服传感器,直接测量16周累积(入组至最终访视)和10天依从性。
- 每月访视时定量干血斑中红细胞内TFV-DP和FTC-TP浓度,并在稳态(第12或16周)以中位数(四分位距)汇总。
- 采用线性混合效应模型评估与TFV-DP/FTC-TP相关的因素。
主要发现
- 92%的参与者完成第12或16周访视(94%使用未增强抗逆转录病毒治疗)。
- 累积依从性<85%(7/72)、85%-<95%(9/72)和≥95%(56/72)者的TFV-DP分别为2696(2039-4108)、3117(2332-3339)和3344(2605-4293)fmol/punches。
- 10天依从性<85%(14/77)、85%-<95%(6/77)和≥95%(57/77)者的FTC-TP分别为3.52(2.64-4.48)、4.58(4.39-5.06)和4.96(4.21-6.26)pmol/punches。
- 调整累积依从性后,TFV-DP在使用增强抗逆转录病毒治疗、较低体重指数和非黑人参与者中更高。
- 所有累积依从性和10天依从性均≥85%的参与者,其TFV-DP分别≥1800 fmol/punches和FTC-TP≥2.5 pmol/punches。
关键数值与推荐
- TFV-DP ≥1800 fmol/punches和FTC-TP ≥2.5 pmol/punches为未增强TAF/FTC为基础抗逆转录病毒治疗依从性≥85%的干血斑基准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: QUANTI-TAF aimed to establish tenofovir-diphosphate (TFV-DP)/emtricitabine-triphosphate (FTC-TP) adherence benchmarks in dried blood spots (DBS) for persons with human immunodeficiency virus (PWH) receiving tenofovir alafenamide/emtricitabine (TAF/FTC)-based antiretroviral therapy (ART). METHODS: For 16 weeks, PWH received TAF/FTC-based ART co-encapsulated with an ingestible sensor to directly measure cumulative (enrollment to final visit) and 10-day adherence. At monthly visits, intraerythrocytic concentrations of TFV-DP and FTC-TP in DBS were quantified and summarized at steady-state (week 12 or 16) as median (interquartile range). Linear mixed-effects models evaluated factors associated with TFV-DP/FTC-TP. RESULTS: Eighty-four participants (11% female, 4% transgender) predominantly receiving bictegravir/TAF/FTC (73%) were enrolled. Ninety-two percent completed week 12 or 16 (94% unboosted ART). TFV-DP for <85% (7/72), 85%-<95% (9/72), and ≥95% (56/72) cumulative adherence was 2696 (2039-4108), 3117 (2332-3339), and 3344 (2605-4293) fmol/punches. Adjusting for cumulative adherence, TFV-DP was higher with boosted ART, lower body mass index, and in non-Black participants. FTC-TP for <85% (14/77), 85%-<95% (6/77), and ≥95% (57/77) 10-day adherence was 3.52 (2.64-4.48), 4.58 (4.39-5.06), and 4.96 (4.21-6.26) pmol/punches. All participants with ≥85% cumulative and 10-day adherence had TFV-DP ≥1800 fmol/punches and FTC-TP ≥2.5 pmol/punches, respectively. Low-level viremia (HIV-1 RNA 20-199 copies/mL) occurred at 18% of visits in 39% of participants with similar TFV-DP (3177 [2494-4149] fmol/punches) compared with suppressed visits (3279 [2580-4407] fmol/punches). CONCLUSIONS: TFV-DP ≥1800 fmol/punches and FTC-TP ≥2.5 pmol/punches represent DBS benchmarks for ≥85% adherence to unboosted TAF/FTC-based ART. Among PWH with high adherence, low-level viremia was common. CLINICAL TRIALS REGISTRATION: NCT04065347.
引用
- Coyle RP, Morrow M, Mann SC, et al. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine-Based Antiretroviral Therapy (QUANTI-TAF). Clin Infect Dis. 2024. PMID: 38636950. doi:10.1093/cid/ciae212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。